MTOR and hepatocellular carcinoma: Taken together, these data indicated that the combination of ATO/PTL endows the HCC cell lines with much stronger autophagic activity than each reagent via inhibiting the PI3K/Akt/mTOR pathway, which may weaken the anti-tumor efficacy of the combination of PTL and ATO.